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Background: Angiogenesis is an essential process during tumor development and growth. The murine dorsal
skinfold window chamber model has been used for the study of both tumor microvasculature and other vascular
diseases, including the study of anti-angiogenic agents in cancer therapy. Hyperspectral imaging of oxygen status
of the microvasculature has not been widely used to evaluate response to inhibition of angiogenesis in early tumor
cell induced vascular development. This study demonstrates the use of two different classes of anti-angiogenic
agents, one targeting the Vascular Endothelial Growth Factor (VEGF) pathway involved with vessel sprouting and
the other targeting the Angiopoietin/Tie2 pathway involved in vascular destabilization. Studies evaluated the tumor
microvascular response to anti-angiogenic inhibitors in the highly angiogenic renal cell carcinoma induced
angiogenesis model.
Methods: Human renal cell carcinoma, Caki-2 cells, were implanted in the murine skinfold window chamber. Mice
were treated with either VEGF pathway targeted small molecule inhibitor Sunitinib (100 mg/kg) or with an anti-Ang-2
monoclonal antibody (10 mg/kg) beginning the day of window chamber surgery and tumor cell implantation.
Hyperspectral imaging of hemoglobin saturation was used to evaluate both the development and oxygenation of
the tumor microvasculature. Tumor volume over time was also assessed over an 11-day period post surgery.
Results: The window chamber model was useful to demonstrate the inhibition of angiogenesis using the VEGF
pathway targeted agent Sunitinib. Results show impairment of tumor microvascular development, reduced oxygenation
of tumor-associated vasculature and impairment of tumor volume growth compared to control. On the other hand, this
model failed to demonstrate the anti-angiogenic effect of the Ang-2 targeted agent. Follow up experiments suggest that
the initial surgery of the window chamber model may interfere with such an agent thus skewing the actual effects on
angiogenesis.
Conclusions: Results show that this model has great potential to evaluate anti-VEGF, or comparable, targeted agents;
however the mere protocol of the window chamber model interferes with proper evaluation of Ang-2 targeted
agents. The limitations of this in vivo model in evaluating the response of tumor vasculature to anti-angiogenic
agents are discussed.
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Angiogenesis, the formation of new blood vessels from
pre-existing ones, is an essential process in tumor devel-
opment and growth [1]. Angiogenesis can be separated
into two key steps, (a) vascular destabilization mediated
by the Angiopoietin/Tie2 axis and (b) endothelial cell ac-
tivation heavily influenced by the Vascular Endothelial
Growth Factor (VEGF) and its receptor VEGFR-2 [2,3].
The use of VEGF axis targeted anti-angiogenic agents has
become a standard of care in many tumor settings in the
last decade. However, their clinical efficacy has been lim-
ited [4,5]. Recently, a new class of anti-angiogenic agents
targeting Angiopoetin-2 (Ang-2) has emerged in hopes to
circumvent lack of response or resistance seen with VEGF
targeted agents [6]. Currently many agents are being eval-
uated both in preclinical and clinical settings including
targets not mentioned above [4,6].
The dorsal skinfold window chamber is commonly
used to evaluate the microvasculature in various settingsA 
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Figure 1 Human renal cell carcinoma, Caki-2, tumor growth in the wi
nude mice and tumor cells injected (2 × 104) subcutaneously into the wind
chamber over time. Hyperspectral imaging of hemoglobin saturation proviin vivo. The model involves surgical implantation of a ti-
tanium window onto exposed microvasculature on the
dorsal skin of mice [7,8]. This method has been used to
evaluate angiogenesis in a variety of processes such as
endometriosis and tumor development; it was also used
to evaluate the early phases of preclinical development
of Bevacizumab in the 1990s [9-14]. Hyperspectral im-
aging of hemoglobin saturation has allowed for the
evaluation of oxygenation and hypoxia, oxygen transport
dynamics and characterization of the abnormal vascular
physiology and acute oxygen fluctuations within the
tumor microvasculature [15-18]. Tumor microvascular
response to various therapies such as radiotherapy, vas-
cular disrupting agents and sickled erythrocytes has also
been evaluated using this imaging system [19-21]. Appli-
cations other than the tumor microvasculature have also
been explored for example the characterization of ar-
teriovenous malformation in hereditary hemorrhagic
talengiectasia, the formation of spontaneous and induced 60 70 80 90 




ndow chamber. (A) Titanium chambers are surgically implanted in
ow. (B) Tumor cell induced microvascular development in the window
de oxygenation status of tumor microvasculature.
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cell localization and tissue damage in particle based
vaccines [18,22,23].
Anti-angiogenic agents are commonly evaluated in vivo
using either matrigel plug or intradermal assays as well
as histological assessments of the number and function
of tumor associated vasculature [24]. To date, the murine
dorsal skinfold window chamber model combined with
hyperspectral imaging has not been widely utilized. This
model allows for the evaluation of tumor response to
anti-angiogenic agents and assesses not only the vascular
density of the tumor but also its oxygenation status. Real
time assessment of tumor vasculature at microvessel
resolution has tremendous potential to answer several
important questions regarding aspects of vascular response
to anti-angiogenics such as oxygenation status of the vas-
culature. The current study evaluated both a VEGF and
































Figure 2 VEGF inhibition in Caki-2 cell induced angiogenesis. Mice be
inhibitor (Sunitinib). (A) Tumor volume and (B) tumor microvascular respon
percentile; control (n = 8), Sunitinib (n = 7) (combination of two independerenal cell carcinoma cell induced angiogenesis. Limitations
of this model in this particular setting quickly became
apparent and are discussed here.
Materials and methods
Reagents
Mouse Ang-2 ELISA kit (MBS728992) was purchased
from MyBioSource (San Diego, CA). MECA-32 (rat anti-
mouse Cat# 120501) was purchased from BioLegend
(San Diego, CA). NG2 (rabbit anti-mouse Cat# AB5320)
was obtained from Millipore (Temecula, CA). AlexaFluor
488 (donkey anti-rabbit) and AlexaFluor 594 (donkey
anti-rat) were purchased from Invitrogen (Grand Island,
NY). VectaShield mounting medium with DAPI was pur-
chased from Vector Labs Inc. (Burlingame, CA). Tissue-
Tek OCT Compound was purchased from Sakura Finetek
(Torrance, CA). 2-methylbutane was obtained from
Thermo Fisher Scientific (Waltham, MA).10 11 12
**









aring window chambers with Caki-2 tumors were treated with VEGF
se to Sunitinib was evaluated compared to control. Median + 90/10
nt experiments). **, p < 0.01, Mann–Whitney U-Test.
Biel et al. Vascular Cell 2014, 6:17 Page 4 of 11
http://www.vascularcell.com/content/6/1/17Cell culture
The human clear cell renal cell carcinoma, Caki-2, cell line
was originally received from Dr. Susan Knox (Stanford
University). Caki-2 was grown in Dulbecco’s modified
minimum essential medium (D-MEM, Invitrogen, Grand
Island, NY) supplemented with 10% FBS (Invitrogen,
Grand Island, NY), 1% penicillin-streptomycin (Invitrogen,
Grand Island, NY), and 1% 200-mmol/L L-glutamine
(Invitrogen, Grand Island, NY). Cells were kept at 37°C,
5% CO2.
Drug preparation
Ketamine and xylazine were purchased from Webster
Veterinary (Devens, MA) and prepared in sterile saline.
The anti-Ang-2 monoclonal antibody was kindly pro-
vided by MedImmune, LLC. The stock solution (5 mg/ml)
was diluted to the working dose (10 mg/kg) in so-
dium citrate buffer solution. Stock solutions were kept
at −80°C and working concentrations at 4°C. The VEGFR
small molecule inhibitor Sunitinib was obtained from
LC Laboratories (Woburn, MA) and stored at −20°C.
Working dose of Sunitinib was prepared fresh everyday
by making stock and diluent buffers of citric acid
monohydrate and sodium citrate dihydrate at pH 6.8
and 3.2 respectively. A 1:7 stock to diluent solution was
made (~pH 3.3) and acidified to pH 1.0, Sunitinib was
dissolved, and then the solution was adjusted to pH 3.5.

























Figure 3 Tumor vasculature after VEGF inhibition. Immunohistochemic
Mann–Whitney U-Test. Representative images of the median of each group
with 20× objective; scale bar = 140 μm.Window chamber surgery and tumor initiation
All in vivo procedures were conducted in agreement
with a protocol approved by the University of Florida
Institutional Animal Care and Use Committee. Dorsal skin-
flap window chamber surgeries were carried out as previ-
ously described by Moy and colleagues [7]. Briefly, female
athymic nu/nu mice (Harlan Laboratories, Indianapolis, IN)
were surgically implanted with a titanium window chamber
on the dorsal skinflap. During the surgical procedure mice
were anesthetized via intraperitoneal (IP) injection of keta-
mine (100 mg/kg) and xylazine (10 mg/kg). Human renal
cell carcinoma, Caki-2, tumor was initiated in the window
chamber during surgery by injecting cells (2 × 104 in 10 μl
volume) subcutaneously in the dorsal skinflap prior to pla-
cing a 12 mm diameter number 2 round glass cover slip
(Erie Scientific, Portsmouth, NH) over the exposed skin.
Post surgical procedure, animals were housed in an envir-
onmental chamber maintained at 33°C and 50% humidity
with standard 12 hr light/dark cycles for the remainder of
the study.
Treatment of window chamber tumors
Mice were treated with Sunitinib (100 mg/kg) daily via oral
gavage or with the anti-Ang-2 antibody (10 mg/kg) every
3 days via IP injection, starting the day of window chamber
surgery/tumor initiation up to day 11 post-surgery when
mice were euthanized. During the study, tumors were mea-
sured everyday using calipers and tumor volume (mm3)
was calculated, assuming that the tumor volume was0 
100 
al analysis of tumors at study endpoint. Line, median; *, p < 0.05;
. Red, MECA. Images taken with Zeiss Axioplan Imaging2 microscope
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volume = ½ [π/6 × d1 × d2 × height]. Statistical signifi-
cance was determined using the Mann–Whitney U-Test
at p < 0.05.
Hyperspectral imaging
The spectral imaging system, image acquisition, and
image processing methods have previously been de-
scribed [7,15]. Briefly, window chamber tumors were
imaged daily using a Zeiss AxioImager microscope (Carl
Zeiss, Inc., Thornwood, NY) with 100-W tungsten halogen
lamp, CCD camera thermoelectrically cooled to −20°C
(DVC Co., Austin, TX; Model no.1412 AM-T2-FW) and
C-mounted liquid crystal tunable filter (LCTF) (CRI Inc.,
Woburn, MA). Tuning of the LCTF and image acquisition
with the CCD camera was automatically controlled with
LabVIEW8 software (National Instruments Corp., Austin,
TX). Vascular hemoglobin saturation measurements and































Figure 4 Ang-2 inhibition in Caki-2 cell induced angiogenesis. Mice be
inhibitor (monoclonal antibody). (A) Tumor volume and (B) tumor microva
control. Median + 90/10 percentile; control (n = 8), anti-Ang-2 (n = 7) (combMatlab software (The Mathworks Inc., Natick, MA).
During imaging mice were placed on a heated plat-
form and anesthetized with 1-2% isofluorane (Webster
Veterinary, Devens, MA) in air.
Immunohistochemistry
Eleven days post surgery mice were euthanized with
euthasol (0.01 ml/g) (Webster Veterinary, Devens, MA),
titanium window chambers were removed and tumors
were fresh frozen in OCT and methylbutane. Tumors
were sectioned at 5 μm thickness using Leica CM 3050S
cryostat (Leica Microsystems Inc., Buffalo Grove, IL);
sections were placed on superfrost plus gold slides
(Thermo Fisher Scientific Inc., Waltham, MA) and kept
at −80°C until immunohistochemical staining. Tissue
sections were acetone fixed for 10 min, blocked in 2%
normal horse serum, and incubated overnight at 4°C
with MECA-32 and NG2 primary antibodies, at room
temperature with secondary antibodies AlexaFluor 4880 60 70 80 90 
100% 
Anti-Ang-2 
BF Hb BF Hb 





aring window chambers with Caki-2 tumors were treated with Ang-2
scular response to the Ang-2 inhibitor was evaluated compared to
ination of two independent experiments).
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Zeiss Axioplan 2 imaging microscope (Carl Zeiss, Inc.,
Thornwood, NY) with EXFO X-Cite 120 light source
(Lumen Dynamics Group Inc., Ontario, Canada). Images
were taken with a Retiga EXi Fast digital CCD camera
(QImaging, British Columbia, Canada) and processed in
OpenLab5 software (PerkinElmer Inc., Waltham, MA);
Rhodamine for MECA-32/AlexaFluor594, FITC for NG-
2/AlexaFluor488 and DAPI filters were used. Vessel
counts were obtained by taking up to ten random fields/
tumor at 20× objective, counting the number of vessels
in each random field. The number of peri-endothelial
cell covered vessels was counted in the tumor periphery
for each tumor. Statistical significance between control
and treated groups was determined using the Mann–
Whitney U-Test at p < 0.05.
Serum angiopoietin-2 levels
Blood from the tail vein was drawn on days 3 and 5 post
surgery from mice (2 mice/group) that (1) did not have
surgery (baseline), (2) that underwent surgery and (3) ones
that underwent surgery and inoculated with tumor cells.
About 100 μl of blood per mouse was collected and placed
on ice for 2 hr to let the blood clot. Blood was then centri-
fuged for 15 min, 4°C at 1000 g. Serum was collected and
stored at −80°C until analysis. Serum Ang-2 levels were
calculated using a mouse-specific Ang-2 ELISA kit. Based
on company recommendation, the manufacturer’s protocol









Figure 5 Tumor vasculature after Ang-2 inhibition. Immunohistochemi
Mann–Whitney U-Test. Representative images of the median of each group
with 20× objective; scale bar = 140 μm.50 μl of 3.3 fold diluted conjugate in 0.9% NaCl per well
and incubate for 2 hr at 37°C; manufacturers protocol was
otherwise followed.
Intradermal angiogenesis assay
All in vivo procedures were conducted in agreement
with a protocol approved by the University of Florida In-
stitutional Animal Care and Use Committee. Female
athymic nu/nu mice were injected intradermally with
105 Caki-2 cells in 10 μl volume at four sites on the ven-
tral surface. Beginning the day prior to tumor cell injec-
tion, mice were treated with either daily oral gavage of
Sunitinib (100 mg/kg) or IP injection of the anti-Ang-2
antibody (10 mg/kg) every 3 days up to six days post
tumor cell inoculation. Mice were then euthanized, tu-
mors measured via calipers and tumor volume (mm3)
calculated, assuming the tumor volume to be an ellips-
oid, using the following equation: tumor volume = π/6 ×
d1 × d2 × height. Skin flaps were then removed and ves-
sels growing into tumor nodules were counted using a
Leica MZ16F dissecting microscope with Leica KL 1500
LCD fiber optic illuminator (Leica Microsystems Inc.,
Buffalo Grove, IL) at 2.5x original magnification. Im-
ages were captured with a Retiga EXi Fast1394 digital
CCD camera (QImaging, British Columbia, Canada) and
OpenLab5 software (PerkinElmer Inc., Waltham, MA).
Statistical significance between control and treated
groups was determined using the Mann–Whitney U-Test
at p < 0.05. 
0 
cal analysis of tumors at study endpoint. Line, median; *, p < 0.05;
. Red, MECA. Images taken with Zeiss Axioplan Imaging2 microscope
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Human renal cell carcinoma, Caki-2, growth in the
window chamber
Renal cell carcinoma is a highly vascularized disease
and anti-angiogenic agents are currently used as both
first and second line treatments in patients. Caki-2
cells, a VHL mutant, highly vascular and aggressively
growing cell line, were implanted into the window
chamber (Figure 1A). Induction of tumor cell induced
angiogenesis was seen at days 5–6 post tumor cell
implantation at which point the tumors quickly ex-
panded and became heavily vascularized with 50-80%
hemoglobin saturation in the microvasculature at day 8
(Figure 1B).
VEGF inhibition impedes tumor and vessel growth in
Caki-2 tumors in the window chamber
Caki-2 tumors grew rapidly and expanded their micro-
vasculature greatly over time with increased oxygenation
































Figure 6 Vascular structure after Ang-2 inhibition. Immunohistochemic
vasculature with pericyte coverage. (B) Tumor vasculature without pericy
number of vessels that maintained pericyte coverage. Line, median; *, p
White arrows show pericyte covered vessels; yellow arrow shows vessels
(pericyte); blue, DAPI. Images taken with Zeiss Axioplan Imaging2 microsthe VEGF inhibitor led to a significant 5.2-fold reduction
in tumor volume (p < 0.01) (Figure 2A) as well as a dra-
matic impairment of tumor vasculature and oxygenation
(Figure 2B). Immunohistochemical analysis of tumor
vasculature at study endpoint revealed a 2.4-fold reduc-
tion in vessel number of the treated groups compared to
control (p < 0.0001) (Figure 3).
Ang-2 inhibition does not affect Caki-2 tumor growth in
the window chamber
Treatment of mice with the Ang-2 inhibitor did not
show impairment of tumor growth or vascular devel-
opment (Figure 4). However, immunohistochemical ana-
lysis of tumor vasculature at study endpoint revealed
a 1.1-fold reduction in the treated groups compared
to control (p < 0.05) (Figure 5). Furthermore, analysis
of the vascular structure revealed a 4-fold increase in
the number of vessels that maintained pericyte cover-




al analysis of vascular structure at study endpoint. (A) Normal
te coverage. Scale bar, 46 μm. (C) Ang-2 inhibition led to increased
< 0.05; Mann- Whitney U-Test. Representative images of each group.
without pericyte coverage. Red, MECA (endothelium); green, NG2
cope with 20× objective; scale bar = 140 μm.
Biel et al. Vascular Cell 2014, 6:17 Page 8 of 11
http://www.vascularcell.com/content/6/1/17VEGF and Ang-2 inhibition in the intradermal
angiogenesis model
To evaluate the inhibition of both the VEGF/VEGFR
and Ang-2/Tie2 pathways in the absence of surgical in-
stallation of dorsal skinflold window chambers an intra-
dermal assay was used. Inhibition of the VEGF/VEGFR
pathway with Sunitinib (100 mg/kg) led to the reduc-
tion of both tumor and vessel growth by 43 (p < 0.001)
(Figure 7A) and 2.5-fold (p < 0.0001) (Figure 7B) respect-
ively compared to control. Treatment of mice with the
anti-Ang-2 antibody (10 mg/kg) led to a reduction of both





























































Figure 7 Ang-2 and VEGF inhibition in the intradermal assay. Mice we
treated with either the Ang-2 inhibitor (10 mg/kg) or Sunitinib (100 mg/kg
(A, C) and the number of tumor cell induced blood vessels (B, D) were de
line, median (n = 12); **, p < 0.01; ***, p < 0.0001; Mann–Whitney U-Test.1.6-fold (p < 0.0001) (Figure 7D) respectively compared to
control.
Surgery associated with the window chamber model led
to an increase in serum Ang-2 levels
The release of Ang-2 from endothelial cells as a wound
healing response has been previously noted [25,26]. The
circulating Ang-2 levels were determined in mice that
underwent surgery. Results show that mice that under-
went surgery had an increased level of Ang-2 in their
circulation compared to control mice that did not re-














re injected intradermally with Caki-2 renal cell carcinoma cells and
) beginning the day prior to tumor cell inoculation. Tumor volume






















No surgery (normal) 
Surgery only  
Surgery + tumor  
Figure 8 Ang-2 serum levels in mice. Levels of Ang-2 in the circulation were determined for mice that underwent window chamber
surgery −/+tumor cell injection and compared to basal levels (no surgery).
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creased the Ang-2 levels in the circulation compared to
mice that only underwent surgery.
Discussion
Vascular-targeted agents that inhibit the formation of
new blood vessels from pre-existing ones have become a
standard of care in several cancer settings over the last
decade [4,27]. A cohort of patients do not respond or
stop responding to treatment with the currently FDA
approved anti-angiogenic agents. As a consequence new
pathways in the angiogenic process have been exploited
as therapeutic targets [4,6].
The murine dorsal skinfold window chamber model
has been previously used to study and understand the
microvasculature of not only tumors but other diseases
as well [7-17,19,21-23]. Recently the use of hyperspec-
tral imaging, to evaluate vascular oxygenation status
through hemoglobin saturation absorption, allowed for
more in depth evaluation of microvascular response to,
among others, vascular-targeted agents and their effect
on the microvasculature [20]. The dorsal skinfold win-
dow chamber model with high resolution hyperspec-
tral imaging, to our knowledge, has not been widely
used to evaluate anti-angiogenic therapy on the early
initiation of angiogenesis and development of tumors.
Ferrara and colleagues have used the window chamber
model with basic imaging techniques to demonstrate
the anti-angiogenic effects of Bevacizumab in preclin-
ical development [11-14]. To date, there are no data inthe literature using this model to evaluate Ang-2 tar-
geted agents.
In the present study, two different classes of anti-
angiogenic agents were evaluated. Sunitinib is a small mol-
ecule tyrosine kinase inhibitor that targets the VEGFR1-3
and PDGFR and has been FDA approved in 2006 as first
line treatment in metastatic kidney cancer [28]. The anti-
Ang-2 monoclonal antibody was used as the Ang-2 tar-
geted agent. Results show that Caki-2 cells injected at
2×104 cells initiate angiogenesis 5–6 days post tumor cell
injection (Figure 1). When Caki-2 tumor bearing mice
were treated with the VEGF inhibitor during an 11 day
period the growth of the tumor was significantly inhibited
by 5.2-fold compared to untreated tumors (Figure 2A).
The development of tumor microvasculature of treated
mice was significantly impaired with sparse and poorly
oxygenated vessels (Figure 2B). Immunohistochemical ana-
lysis of tumors at endpoint further demonstrated the
significantly impaired vasculature of treated mice with a
2.4-fold reduction in the number of vessels compared
to control tumors (Figure 3). The results clearly show
that the window chamber model and hyperspectral im-
aging can be a useful tool to evaluate agents targeting
the VEGF pathway and the response of the tumor and
microvasculature to such treatment. Results nicely demon-
strate not only the inhibition of vascular development but
also the poor oxygenation of the microvasculature that the
tumor possesses.
On the other hand, the results show a different tumor
response to the Ang-2 inhibitor. Mice treated with the
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tumor growth (Figure 4A) compared to untreated tu-
mors nor did it seem to have an effect on the vascular
density or oxygenation of the vessels (Figure 4B). These
results were rather puzzling at first but immunohisto-
chemical analysis revealed a slight but significant reduc-
tion in the vessel number (Figure 5) as well as a highly
significant 4-fold increase in pericyte covered vessels when
tumors were treated with the Ang-2 inhibitor (Figure 6).
Furthermore, previous results showed a significant anti-
angiogenic effect of the Ang-2 inhibitor, which is the op-
posite response that is seen in the window chamber model
[29]. Therefore, the intradermal assay was repeated with
both the VEGF and Ang-2 inhibitors to closely mirror the
experiment conducted in the window chamber model.
Results from the intradermal assay show that VEGF
inhibition led to a significant 43- (Figure 7A) and 2.5-
fold (Figure 7B) reduction in tumor volume and vessel
number respectively compared to control correlating with
the results seen in the window chamber model. Contrary
to results seen with the Ang-2 inhibitor in the window
chamber, the antibody led to a significant 3.1- (Figure 7C)
and 1.6-fold (Figure 7D) reduction in tumor volume and
vessel number compared to control. Similar tumor volume
and vessel results with the VEGF targeted agent but op-
posing results with the Ang-2 targeted agent led to ques-
tions about the difference between the two models. In
general, the sole difference between the intradermal assay
and window chamber model is the initial surgery that is
involved with the window chamber model. Review of the
basic biology of the Ang-2 and VEGF axis in physiological
response to injury led to the hypothesis that perhaps the
surgery involved with the window chamber model leads to
the rapid release of Ang-2 from damaged endothelial cells
when the skinflap is cut to expose the vasculature on the
skin that is spared. The angiopoietin axis is not only in-
volved with the rapid response to vascular injury as a
wound healing response but is also a pro-inflammatory
factor [25,26,30-33]. The surgery to implant the window
chamber could not only elicit a wound healing but also a
pro-inflammatory response.
To support this hypothesis serum samples from mice
that have not received surgery, mice that received sur-
gery and ones with surgery and tumor cell injection were
evaluated at various time points after surgery. Results
demonstrate that mice that received surgery had 1.4- and
1.5-fold higher Ang-2 levels in the serum compared to
basal levels in mice that did not receive surgery at days 3
and 5 post surgery respectively (Figure 8). Furthermore,
mice that received surgery and were injected with tumor
cells had a slightly higher increase of 1.6-fold compared to
baseline at days 3 and 5 post surgery (Figure 8).
In conclusion, the murine dorsal skinfold window
chamber model is a valuable model to evaluate tumormicrovasculature and vascular oxygenation using hyper-
spectral imaging. Cautions with this model should be
taken when assessing the vascular response to thera-
peutic strategies. In this study two different classes of
anti-angiogenic agents were evaluated. The Ang-2/Tie2
axis is important in vascular destabilization while the
VEGF/VEGFR axis plays a role in endothelial cell activa-
tion to proliferate, migrate and form new vessels. While
both axes are essential in physiological angiogenesis such
as wound healing, they nevertheless have very different
roles. Endothelial cells store Ang-2 in Weibel-Palade
Bodies to be able to quickly respond to environmental
changes such as vascular injury [34-36] while VEGF is es-
sential in the formation of new vasculature, a later re-
sponse in wound healing [37]. It is clear that the surgery
involved with the window chamber model upsets the
normal balance of Ang-2 in the microenvironment lead-
ing to skewed results to Ang-2 inhibition. The window
chamber model, however, is a great tool to evaluate the
inhibition of endothelial cell activation and could be uti-
lized to rapidly and effectively evaluate anti-angiogenic
agents in preclinical studies.
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